PROPOFOL INJECTION 10 MG — DIN 02437643
PROPOFOL : 10 MG · FRESENIUS KABI CANADA LTD · EMULSION · wholesale supply in Canada
Health Canada status: MARKETED
What is PROPOFOL INJECTION?
PROPOFOL INJECTION 10 MG contains PROPOFOL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02437643, held by FRESENIUS KABI CANADA LTD, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 01-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROPOFOL INJECTION used for?
Induction and maintenance of general anesthesia; conscious sedation for surgical/diagnostic procedures; sedation during intensive care for intubated, mechanically ventilated adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Propofol cost around the world?
Propofol is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 10 | 43 | BRL███.██ |
| Saudi Arabia | public | 14 | 28 | SAR███.██ |
| South Africa | single exit price | 18 | 27 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 17 | CZK███.██ |
| Italy | ex-factory (classe H) | 17 | 17 | EUR███.██ |
| Greece | producer price (ex-factory) | 14 | 14 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 13 | NOK███.██ |
| Bahrain | retail (max) | 6 | 9 | BHD███.██ |
| United Arab Emirates | public | 5 | 7 | AED███.██ |
| Romania | max producer price | 3 | 6 | RON███.██ |
| United States | acquisition | 2 | 5 | USD███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
189 pack listings across 97 brand entries and 12 price bases, refreshed 07 Sep 2026. Ranges span every Propofol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Propofol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Propofol, across 11 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 2 | 1 | PROPOFOL, PROPOFOL INJECTION | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 1 | 1 | DIPRIVAN 1% | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | PROPOFOL INJECTION | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | PROPOFOL INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 0 | PROPOFOL INJECTION, PROPOFOL-II INJECTION | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | PROPOFOL INJECTION | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | PROPOFOL INJECTION | No marketed DIN |
| STERIMAX INC | 1 | 0 | PROPOFOL INJECTION | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | TEVA-PROPOFOL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | EMULSION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Single-use parenteral product (specific container sizes not listed in provided text, but noted as single-use). |
| Storage | Do not freeze. (Standard storage typically 15-30°C, though specific range not explicitly in snippet, 'Do not freeze' is specified). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Propofol |
|---|---|
| ATC code | N01AX10 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02437643 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2437643 |
| Brand name | PROPOFOL INJECTION |
| Generic / active ingredient | PROPOFOL : 10 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Prescription |
| ATC code | N01AX10 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01AX |
| Current status | MARKETED |
| Status date | 01-Jun-2015 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individually titrate to effect. Induction: 2-2.5 mg/kg (adults <55). Maintenance: 0.1-0.2 mg/kg/min. ICU sedation: 0.005-0.05 mg/kg/min (max 4 mg/kg/h). Use aseptic technique.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to propofol, lipid emulsions, eggs/egg products, or soybeans/soy products. Contraindicated for sedation of children 18 years or younger receiving intensive care.
Warnings and precautions
Risk of fatal respiratory complications without airway care. Risk of hypotension, apnea, and sepsis if aseptic technique fails. Monitor for Propofol Infusion Syndrome (PIS) and lipemia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIPRIVAN 1% | 10 MG | EMULSION | ASPEN PHARMACARE CANADA INC. | MARKETED | 02018950 |
| PROPOFOL INJECTION | 10 MG | EMULSION | BAXTER CORPORATION | MARKETED | 02244379 |
| PROPOFOL INJECTION | 10 MG | EMULSION | MARCAN PHARMACEUTICALS INC | MARKETED | 02525879 |
| PROPOFOL | 10 MG | EMULSION | BAXTER CORPORATION | CANCELLED POST MARKET | 02468336 |
| PROPOFOL INJECTION | 10 MG | EMULSION | STERIMAX INC | APPROVED | 02559692 |
| PROPOFOL INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02236887 |
| PROPOFOL INJECTION | 10 MG | EMULSION | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02241504 |
| PROPOFOL INJECTION | 10 MG | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02242973 |
| PROPOFOL-II INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02376865 |
| TEVA-PROPOFOL | 10 MG | EMULSION | TEVA CANADA LIMITED | DORMANT | 02437961 |
2 · Same class — other molecules in ATC N01AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ketamine | KETALAR · KETAMINE HYDROCHLORIDE INJECTION SDZ · KETAMINE HYDROCHLORIDE INJECTION USP · KETAMINE HYDROCHLORIDE INJECTION, USP · +1 more | 13 | 7 | Yes |
| Propofol | DIPRIVAN 1% · PROPOFOL · PROPOFOL INJECTION · PROPOFOL-II INJECTION · +1 more | 11 | 4 | Yes |
| Nitrous Oxide | NITROUS OXIDE · NITROUS OXIDE 100% · NITROUS OXIDE 99% · NITROUS OXIDE U.S.P. · +1 more | 6 | 3 | Yes |
| Nitrous Oxide,Combinations | ALNOX GAS · LIQUI-MED ANALGESIC GAS · MEOPA · NITROUS OXIDE IN OXYGEN | 4 | 3 | Yes |
| Etomidate | ETOMIDATE INJECTION USP · ETOMIDATE INJECTION, USP · TOMVI | 3 | 2 | Yes |
| Droperidol | INAPSINE INJ 2.5MG/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01AH | Alfentanil · Anileridine · Fentanyl · Fentanyl, Combinations · Remifentanil · +1 more | 33 | 12 |
| N01AB | Desflurane · Enflurane · Halothane · Isoflurane · Sevoflurane | 19 | 6 |
| N01AF | Methohexital · Thiopental | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PROPOFOL INJECTION called?
The same molecule, Propofol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PROPOFOL | Latin | Bahrain, Brazil |
| DIPRIVAN | Latin | Bahrain, Brazil, Morocco |
| ANESIA | Latin | Czechia, Saudi Arabia |
| LIPURO | Latin | Brazil |
| Propofol-Farmak | Latin | Saudi Arabia |
| Profast | Latin | Norway |
| PROPOFOL BAXTER | Latin | Czechia |
| Propofol-Lipuro | Latin | Bahrain, Norway |
| PROPOFOL MCT/LCT FRESENIUS | Latin | Czechia |
| PROPOVAN | Latin | Brazil |
| PROVIVE | Latin | Brazil |
| OPONAP® | Latin | Brazil |
| Propolipid | Latin | Norway |
| HYFOL | Latin | Brazil |
| POFOL | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.